CA 15-3, Ceruloplasmin and tissue polypeptide specific antigen as a tumour marker panel in breast cancer by Özyilkan, Ö et al.
June 2000 EAST AFRICAN MEDICAL JOURNAL 291
East African Medical Journal Vol. 77 No. 6 June 2000
CA 15-3, CERULOPLASMIN AND TISSUE POLYPEPTIDE SPECIFIC ANTIGEN AS A TUMOUR MARKER PANEL IN BREAST CANCER
Ö. Özyilkan, MD, Associate Professor, Bayindir Hospital, Department of Medical Oncology, Ankara, Turkey, E. Baltali, MD, Professor, and S. Kirazli, Medical Laboratory
Technician, Hacettepe University Institute of Oncology, Ankara, Turkey.
Request for reprints to: Dr. Ö. Özyilkan, Çelik sitesi B blok, 42, sokak 64/13, Yukari Dikmen Mah., Oran, TR 06450, Ankara, Turkey.
CA 15-3, CERULOPLASMIN AND TISSUE POLYPEPTIDE SPECIFIC ANTIGEN AS A TUMOUR
MARKER PANEL IN BREAST CANCER
Ö. ÖZYILKAN,  E. BALTALI and S. KIRAZLI
ABSTRACT
Background: Tumour markers along with other tests, may be useful in the assessment of the
prognosis, monitoring response to treatment and early detection of metastases in breast
cancer. The most commonly used breast cancer antigen is CA 15-3.
Objective: To examine the value of CA 15-3, ceruloplasmin and tissue polypeptide specific
antigen (TPS) panel in the monitoring of breast cancer.
Subjects: Serum concentrations of CA 15-3, ceruloplasmin and TPS were measured in 90
women: Fifteen controls, sixteen patients with benign breast disease (BBD), thirty one
patients in remission and twenty eight patients with active breast cancer.
Results: The results of CA 15-3, ceruloplasmin and TPS estimates were separated into four
groups. The patients not in remission were found to have significantly higher levels of
CA 15-3 (p<0.0001) and ceruloplasmin (p<0.0001) compared with the other three groups.
The difference between the patients in remission, BBD and the control group was not
statistically significant (p>0.05) for CA 15-3 and ceruloplasmin. The difference for TPS
between the patients in remission and the patients with active breast cancer was not
statistically significant (p>0.05). The sensitivities of CA 15-3, ceruloplasmin, and TPS for
detecting active breast cancer were 75.0%, 75.0%, and 78.0%, respectively.
Conclusion: The highest sensitivity for active breast cancer detection was obtained by the
combined use of three tumour markers. We concluded that there may be an advantage in
using panels in the follow up of breast cancer patients, although so far such tests have too low
a specificity to be of practical value in screening.
INTRODUCTION
As understanding of the pathophysiology of cancer
increases, the role of tumour markers becomes more
important in the management of cancer patients.
Classically, such markers are synthesised by tumour cells
and released into the circulation but they may also be
produced by normal tissues in response to invasion by
cancer cells(1,2). These markers may include a variety of
enzymes, hormones and antigens but, to-date, most have
been used in conjunction with other tests for determining
the disease state, response to surgery, chemotherapy and
radiation therapy(2,3). The most recently discovered breast
cancer antigen CA 15-3, a serum muci-glycoprotein, has
been identified by reaction with two monoclonal
antibodies(4,5). Clinical studies indicated a good
correlation between CA 15-3 and breast cancer(5,6).
Serum ceruloplasmin has been reported to be a useful
marker of disease activity in patients with carcinoma of
the breast, lung, gastrointestinal tract, acute leukaemias
and Hodgkin’s and non-Hodgkin’s lymphomas(7-10).
The possible role of ceruloplasmin in oncogenesis is not
clear, but, it has been suggested that it may be involved in
angiogenesis and neovascularisation at the site of tumour
growth. Breast cancer cell lines have been found to contain
ceruloplasmin mRNA whilst normal breast cells do not
express this gene(6). Tissue polypeptide specific antigen
(TPS) is a polypeptide marker and high TPS serum levels
appear to reflect increased cell proliferative activity.
Elevated concentrations of TPS have been detected in
association with a wide variety of malignancies, including
breast cancer(11-13).
In this study, we assessed the individual and combined
value of CA 15-3, ceruloplasmin, and TPS measurement
in patients with benign and malignant breast diseases.
MATERIALS AND METHODS
This study included 16 female patients with benign breast
disease (BBD), 59 female patients with histologically documented
carcinoma of the breast and 15 healthy female volunteers. All the
patients were from the Division of Medical Oncology at the
Hacettepe University Hospital. The control group of healthy
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females was clinically negative for breast disease. Their median
age was 36 years (range 18-56 years). The histological
examination of the BBD revealed seven fibrocystic disease,
eight fibroadenoma and one papilloma. The median age of this
group was 31.5 years (range 17-45 years). The median age of the
breast cancer patients was 45 years (range 27-70 years) and 28
out of 59 patients with breast cancer had metastatic disease or
relapse while the remaining 31 were in remission. Twelve of the
15 patients in remission were on adjuvant therapy (chemo- or
hormonal) at the time of this study following a radical or
modified radical mastectomy with or without radiotherapy.
None of the patients or healthy volunteers had laboratory or
clinically proven evidence of infection, primary inflammatory
disease, thyrotoxicosis, pregnancy, cirrhosis or proteinuria when
blood samples were collected. Serum ceruloplasmin and
C-reactive protein (CRP) were measured using a radial
immunodiffusion technique (Binding Site, UK), CA 15-3 levels
by an immunoradiometric assay technique (Centocor IRMA),
and TPS levels by a TPS-ELISA kit (Beki Diagnostics, Bromma,
Sweden).
Difference of the means between the groups were analysed
by one-way ANOVA and Kruskall-Wallis tests. The relationships
between the markers were analysed using linear regression
analysis.
RESULTS
The results of the CA 15-3, ceruloplasmin, and TPS
were separated into four groups: healthy volunteers, patients
with BBD, breast cancer patients in remission and breast
cancer patients not in remission as shown in Figures 1-3.
Figure 1
Distribution of serum CA 15-3 levels in patients with active breast
cancer (relapse or metastases), breast cancer in remission, benign
breast disorders, and a control group
Figure 2
Distribution of serum ceruloplasmin levels in patients with active
breast cancer (Relapse or metastases), breast cancer in remission,
benign breast disorders, and a control group
Figure 3
Distribution of serum TPS levels in patients with active breast cancer
(relapse or metastases), breast cancer in remission, benign breast
disorders, and a control group
The mean levels of the four groups are shown in
Table 1. The patients not in remission were found to have
significantly higher levels of CA 15-3 (p<0.0001) and
ceruloplasmin (p<0.0001) compared with the other three
groups. Although the difference for TPS between the
patients in remission and the patients with active breast
cancer was not statistically significant (p>0.05), both
groups had higher levels than patients with BBD and
healthy volunteers (p<0.01). All women in the four groups
had serum CRP concentration within normal limits, that
is, less than 6.0 mg/l. There were positive correlations
between the CA 15-3 and the serum ceruloplasmin levels
(r=0.322; p=0.002) and also between CA 15-3 and TPS
levels (r=0.233; p=0.027). There was not any correlation
between ceruloplasmin and TPS (r=0.200; p>0.05).
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hope of finding a blood test for cancer, but none of them
has had such sensitivity and specificity that it could
replace conventional diagnostic methods(12). Tumour
markers may be useful, along with other tests, in the
assessment of the prognosis, monitoring response to
treatment and the early detection of metastases(9,11,15-
17).
CA 15-3, the most commonly used tumour marker in
breast cancer, was shown to be increased in 60% of
patients with metastases whereas in patients without
metastases, only about 30% had increased levels. The
principal application of CA 15-3 assay is for monitoring
the course and therapeutic response of  breast cancer(4,18).
In our study, we found higher levels of CA 15-3 in patients
with active breast cancer compared to patients in remission,
similar to other series(14,18,19).
In a study by Schapira and Schapira (20), the
ceruloplasmin levels were found to be elevated in 89% of
103 patients with breast carcinoma and then fell by 35% as
soon as patients responded to treatment. They also showed
that the ceruloplasmin levels of patients with breast
carcinoma increased 16-34 weeks before their metastases
became clinically overt. In our previous study, we suggested
that ceruloplasmin could be used as a tumour marker for
the follow up of breast cancer patients(21). In the present
study, we again found serum ceruloplasmin levels valuable
in detecting active breast cancer. Several clinical studies
have been published on TPS determination in women with
breast cancer. Elevated TPS serum levels are reported
with frequencies varying between 31% and 71%(12,22,23).
In our trial, we found elevated TPS serum levels in 78% of
patients with active breast cancer patients.
The sensitivity of a tumour marker is the percentage
of test results which are correctly positive in the presence
of a tumour and it does not show the false positive results
in the control groups, so it may be valuable in the monitoring
of the response to treatment and the early detection of
metastases or relapse in patients with histopathologically
documented breast cancer. If the number of false negative
cases are low, the negative predictive value which identify
those individuals who truly do not have the disease among
all individuals whose screening tests are negative would
be high(4). Specificity and positive predictive values are
more important in the detection of breast cancer and
tumour markers are not applicable as screening tests at
present(2,25,26). As a result, a marker with high sensitivity
and high negative predictive value would be the most
suitable parameter for the follow up of patients in
combination with other tests. There have been many
attempts to use multivariate and discriminant analyses to
improve the sensitivity and specificity of tumour markers.
A variety of markers, each of which had been reported to
be elevated in patients with cancer of the breast, were
combined to see if multivariate analysis would yield
information not available by the use of one marker
alone(11,26-29). In this study, we examined the value of
CA 15-3/ceruloplasmin/TPS panel in the monitoring of
breast cancer and found that this panel increased the
Table 1
Mean (S.E.) CA  15-3, ceruloplasmin and TPS values in study groups
CA 15-3 (U/mL) Ceruloplasmin (mg/L) TPS (U/L)
Relapse or
metastatic 121.8 ± 25.0 360.6 ± 18.0 325.9 ± 110.4
(5.6-530.0) (271.2-707.6) (37.4-2760.0)
Remission 21.0 ± 2.8 283.2 ± 10.3 184.0 ± 48.7
(7.3-76.9) (221.1-409.6) (25.6-1133.0)
Benign breast
disease 17.9 ± 1.7 250.0 ± 13.8 58.9 ± 3.4
(3.2-29.0) (167.8-375.0) (42.4-81.2)
Control group 17.2 ± 1.2 249.9 ± 22.6 64.0 ± 9.6
(10.3-29.4) (167.8-525.2) (34.4-181.0)
Table 2
CA 15-3, ceruloplasmin and TPS values in study groups
Positive  Negative
Marker Sensitivity Specificity predictive predictive
value  value
% % % %
CA 15-3 75.0 87.0 75.0 88.5
Ceruloplasmin 75.0 74.1 56.7 86.7
TPS 78.0 53.2 43.1 84.6
CA 15-3 and/or
Ceruloplasmin 89.2 70.9 58.1 93.6
CA 15-3 and/or
TPS 100.0 48.3 46.6 100.0
Ceruloplasmin and/or
TPS 96.4 41.9 42.8 96.2
CA 15-3 and/or
Ceruloplasmin and/or
TPS 100.0 43.5 44.4 100.0
The cut-off  levels (75% - 78% sensitivity) determined
for each test were 25.0 U/ml for CA 15-3, 285.0 mg/l for
ceruloplasmin and 70.0 U/l for TPS. Using these cut-off
levels, the positive predictive values for CA 15-3,
ceruloplasmin and TPS were 75.0%, 56.7%, 43.1%,
respectively and negative predictive values were 88.5%,
86.7%, and 84.6%, respectively. By the combined use of
tumour markers the sensitivity for active breast cancer
detection was increased. The results are summarised in
Table 2. Two breast cancer patients in remission with
elevated CA 15-3 and TPS levels developed active disease
during the six-month follow up.
DISCUSSION
Clinical examination, mammography, fine needle
aspiration biopsy and open surgical biopsy are established
diagnostic methods in breast cancer and the final diagnosis
of cancer should be based on histopathology(14). In breast
cancer many tumour markers have been studied in the
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sensitivity and negative predictive value compared to the
single marker tests (Table 2).
In conclusion, the combined use of tumour markers
may be valuable in detecting relapse or metastases in
breast cancer patients, although the use of the CA 15-3/
ceruloplasmin/TPS panel is not of practical value in
screening because of its low specificity.
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